Table 2.
Responses details, stratification by BM response
| Characteristics | All patients, n = 58 | BM-NR, n = 29 | BM-PR, n = 16 | BM-CR, n = 13 |
|---|---|---|---|---|
| Initial HR, no. (%) | 54 (93) | 26 (90) | 15 (94) | 13 (100) |
| Last HR, no (% of initial HR) | 22 (41) | 7 (27) | 5 (33) | 9 (69) |
| Duration of HR, months (range) | 90 (10–101) | 50 (10–98) | 69 (17–96) | 87 (59–101)* |
| Initial MR, no. (% of JAK2+), type | 33/44 (75) 9 CMR, 20 PMR, 4 mMR |
15 (68) 2 CMR, 11 PMR, 2 mMR |
8 (89) 6 PMR, 2 mMR |
10 (91) 7 CMR*, 3 PMR |
| Last MR, no (% of initial overall MR), type | 22 (67) 9 CMR; 4 PMR, 9 mMR |
7 (47)a
2 CMR, 5 mMR |
6 (75) 3 PMR, 3 mMR |
9 (90) 7 CMR, 1 PMR, 1 mMR |
| Time to BM response, months (range) | 52 (12–72) | NA | 54 (12–72) | 52 (30–72)b |
| BM response duration, months (range) | 36 (12–66) | NA | 36 (12–66) | 30 (24–52) |
| Last BM response, no (% of initial), type | 9 BM-CR; 14 BM-PR | NA | 14 BM-PR (88) 2 BM-NR (12) |
9 BM-CR (69) 4 BM-NR (31) |
| Vascular adverse event on therapy, No (%) | 6 (10) | 3 (10) | 2 (13) | 1 (8) |
| MF transformation on therapy, no (%) | 4 (7) | 4 (14) | 0 | 0 |
| Duration of therapy, months (range) | 80 (15–107) | 75 (25–205) | 85 (77–107) | 83 (15–101) |
| Total median follow-up, months (range) | 84 (36–107) | 81 (36–105) | 94 (67–107) | 93 (83–106) |
| On study at last follow-up, no (%) | 32 (55) | 10 (35) | 13 (81) | 9 (69)* |
DX diagnosis, HR hematologic response, MR molecular response
* p < 0.05
aOne patient was not evaluable for subsequent MR
b8/13 patients with BM-CR (61%) achieved complete resolution of reticulin fibrosis (MF-0) after a median of 63 months on therapy (range 30–72); the remaining 5 patients has decreased their BM fibrosis to MF 0/1 after a median of 48 months (range 30–69) on therapy